CD276 and neoplasm: Patients with B7‐H3 expression in tumor cells had the poorest prognosis, with a median survival expectation of only 32 months in comparison to 52 and 84 months in the stromal region B7‐H3 expression and negative B7‐H3 expression groups, respectively (Figure 1C, Table S1).